STC-15
First-in-Class METTL3 Inhibitor
STORM’s lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being evaluated in a Phase 2 study in patients with select sarcomas.
RNA modifying enzymes
RNA (ribonucleic acid) is the only direct product of the human genome and one type of RNA, mRNA, acts as the template to which transfer RNAs (tRNA) bind to drive the synthesis of all proteins, the molecular machines of the cell. RNA is also known to be a key player in cellular decision-making, particularly in the form of non-coding RNA (ncRNA) such as microRNA, piRNA and long non-coding RNA.
